Helen of Troy Limited (HELE) 10-Q 9 Jul 24 2025 Q1 Quarterly report Financial data

Cover page

Cover page - shares	3 Months Ended
	May 31, 2024	Jun. 28, 2024
Entity Addresses [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	May 31, 2024
Document Transition Report	false
Entity File Number	001-14669
Entity Registrant Name	HELEN OF TROY LIMITED
Entity Incorporation, State or Country Code	D0
Entity Tax Identification Number	74-2692550
Entity Address, Address Line One	1 Helen of Troy Plaza
Entity Address, City or Town	El Paso
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	79912
City Area Code	915
Local Phone Number	225-8000
Title of 12(b) Security	Common Shares, $0.10 par value per share
Trading Symbol	HELE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,813,316
Entity Central Index Key	0000916789
Current Fiscal Year End Date	--02-28
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Amendment Flag	false
Other Address
Entity Addresses [Line Items]
Entity Address, Address Line One	Clarendon House
Entity Address, Address Line Two	2 Church Street
Entity Address, City or Town	Hamilton
Entity Address, Country	BM

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	May 31, 2024	Feb. 29, 2024
Assets, current:
Cash and cash equivalents	$ 16,148	$ 18,501
Receivables, less allowances of $7,511 and $7,481	328,097	394,536
Inventory	444,749	395,995
Prepaid expenses and other current assets	30,590	27,012
Income taxes receivable	11,979	7,874
Total assets, current	831,563	843,918
Property and equipment, net of accumulated depreciation of $178,319 and $169,021	334,417	336,646
Goodwill	1,066,730	1,066,730
Other intangible assets, net of accumulated amortization of $191,403 and $186,882	532,378	536,696
Operating lease assets	36,887	35,962
Deferred tax assets, net	3,781	3,662
Other assets	15,195	15,008
Total assets	2,820,951	2,838,622
Liabilities, current:
Accounts payable	245,216	245,349
Accrued expenses and other current liabilities	163,561	181,391
Income taxes payable	11,867	17,821
Long-term debt, current maturities	7,031	6,250
Total liabilities, current	427,675	450,811
Long-term debt, excluding current maturities	741,346	659,421
Lease liabilities, non-current	38,241	37,262
Deferred tax liabilities, net	52,036	41,253
Other liabilities, non-current	12,153	12,433
Total liabilities	1,271,451	1,201,180
Commitments and contingencies
Stockholders' equity:
Cumulative preferred stock, non-voting, $1.00 par. Authorized 2,000,000 shares; none issued	0	0
Common stock, $0.10 par. Authorized 50,000,000 shares; 22,810,412 and 23,751,258 shares issued and outstanding	2,281	2,375
Additional paid in capital	350,200	348,739
Accumulated other comprehensive income	2,797	2,099
Retained earnings	1,194,222	1,284,229
Total stockholders' equity	1,549,500	1,637,442
Total liabilities and stockholders' equity	$ 2,820,951	$ 2,838,622

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	May 31, 2024	Feb. 29, 2024
Statement of Financial Position [Abstract]
Allowance on receivables	$ 7,511	$ 7,481
Property and equipment, accumulated depreciation	178,319	169,021
Other intangible assets, accumulated amortization	$ 191,403	$ 186,882
Cumulative preferred stock, nonvoting, par value (in dollars per share)	$ 1	$ 1
Cumulative preferred stock, non-voting, authorized shares (in shares)	2,000,000	2,000,000
Cumulative preferred stock, non-voting, issued shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized shares (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	22,810,412	23,751,258
Common stock, shares outstanding (in shares)	22,810,412	23,751,258

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Income Statement [Abstract]
Sales revenue, net	$ 416,847	$ 474,672
Cost of goods sold	213,768	259,041
Gross profit	203,079	215,631
Selling, general and administrative expense (“SG&A”)	170,481	167,635
Restructuring charges	1,835	7,355
Operating income	30,763	40,641
Non-operating income, net	100	137
Interest expense	12,543	14,052
Income before income tax	18,320	26,726
Income tax expense	12,116	4,145
Net income	$ 6,204	$ 22,581
Earnings per share (“EPS”):
Basic (in dollars per share)	$ 0.26	$ 0.94
Diluted (in dollars per share)	$ 0.26	$ 0.94
Weighted average shares used in computing EPS:
Basic (in shares)	23,524	24,049
Diluted (in shares)	23,633	24,134

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 6,204	$ 22,581
Other comprehensive income (loss), net of tax:
Cash flow hedge activity - interest rate swaps	925	(3,092)
Cash flow hedge activity - foreign currency contracts	(227)	(623)
Total other comprehensive income (loss), net of tax	698	(3,715)
Comprehensive income	$ 6,902	$ 18,866

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Retained Earnings
Beginning balance (in shares) at Feb. 28, 2023		23,994
Beginning balance at Feb. 28, 2023	$ 1,488,811	$ 2,399	$ 317,277	$ 4,947	$ 1,164,188
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	22,581				22,581
Other comprehensive loss, net of tax	(3,715)			(3,715)
Exercise of stock options (in shares)		5
Exercise of stock options	212	$ 1	211
Issuance and settlement of restricted stock (in shares)		120
Issuance and settlement of restricted stock	0	$ 12	(12)
Issuance of common stock related to stock purchase plan (in shares)		23
Issuance of common stock related to stock purchase plan	2,168	$ 2	2,166
Common stock repurchased and retired (in shares)		(45)
Common stock repurchased and retired	(4,446)	$ (4)	(4,442)
Share-based compensation	9,297		9,297
Ending balance (in shares) at May. 31, 2023		24,097
Ending balance at May. 31, 2023	1,514,908	$ 2,410	324,497	1,232	1,186,769
Beginning balance (in shares) at Feb. 29, 2024		23,751
Beginning balance at Feb. 29, 2024	1,637,442	$ 2,375	348,739	2,099	1,284,229
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,204				6,204
Other comprehensive loss, net of tax	698			698
Exercise of stock options (in shares)		6
Exercise of stock options	352	$ 1	351
Issuance and settlement of restricted stock (in shares)		71
Issuance and settlement of restricted stock	0	$ 7	(7)
Issuance of common stock related to stock purchase plan (in shares)		19
Issuance of common stock related to stock purchase plan	2,006	$ 2	2,004
Common stock repurchased and retired (in shares)		(1,037)
Common stock repurchased and retired	(103,035)	$ (104)	(6,720)		(96,211)
Share-based compensation	5,833		5,833
Ending balance (in shares) at May. 31, 2024		22,810
Ending balance at May. 31, 2024	$ 1,549,500	$ 2,281	$ 350,200	$ 2,797	$ 1,194,222

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Cash provided by operating activities:
Net income	$ 6,204	$ 22,581
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13,836	10,715
Amortization of financing costs	319	308
Non-cash operating lease expense	2,878	2,338
Provision for credit losses	88	3,389
Non-cash share-based compensation	5,833	9,297
Gain on the sale or disposal of property and equipment	(29)	(246)
Deferred income taxes and tax credits	10,445	3,897
Changes in operating capital:
Receivables	64,595	26,733
Inventory	(48,754)	21,572
Prepaid expenses and other current assets	(3,565)	(1,420)
Other assets and liabilities, net	327	(656)
Accounts payable	2,350	36,644
Accrued expenses and other current liabilities	(19,465)	(10,734)
Accrued income taxes	(9,742)	(3,362)
Net cash provided by operating activities	25,320	121,056
Cash used by investing activities:
Capital and intangible asset expenditures	(9,142)	(11,877)
Payments for purchases of U.S. Treasury Bills	(683)	0
Proceeds from the maturity of U.S. Treasury Bills	626	0
Proceeds from the sale of property and equipment	38	246
Net cash used by investing activities	(9,161)	(11,631)
Cash used by financing activities:
Proceeds from revolving loans	314,040	70,150
Repayment of revolving loans	(230,090)	(166,150)
Repayment of long-term debt	(1,563)	(1,563)
Payment of financing costs	(222)	0
Proceeds from share issuances under share-based compensation plans	2,358	2,380
Payments for repurchases of common stock	(103,035)	(4,446)
Net cash used by financing activities	(18,512)	(99,629)
Net (decrease) increase in cash and cash equivalents	(2,353)	9,796
Cash and cash equivalents, beginning balance	18,501	29,073
Cash and cash equivalents, ending balance	16,148	38,869
Supplemental non-cash investing activity:
Capital expenditures included in accounts payable and accrued expenses	$ 5,647	$ 2,579

Basis of Presentation and Relat

Basis of Presentation and Related Information	3 Months Ended
	May 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Related Information	Note 1 - Basis of Presentation and Related Information Corporate Overview The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of May 31, 2024 and February 29, 2024, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended February 29, 2024 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). When used in these notes, unless otherwise indicated or the context suggests otherwise, references to “the Company”, “our Company”, “Helen of Troy”, “we”, “us”, or “our” refer to Helen of Troy Limited and its subsidiaries, which are all wholly-owned. We refer to our common shares, par value $0.10 per share, as “common stock.” References to “the FASB” refer to the Financial Accounting Standards Board. References to “GAAP” refer to accounting principles generally accepted in the United States of America (the “U.S.”). References to “ASU” refer to the codification of GAAP in the Accounting Standards Updates issued by the FASB. References to “ASC” refer to the codification of GAAP in the Accounting Standards Codification issued by the FASB. We incorporated as Helen of Troy Corporation in Texas in 1968 and were reorganized as Helen of Troy Limited in Bermuda in 1994. We are a leading global consumer products company offering creative products and solutions for our customers through a diversified portfolio of brands. Our portfolio of brands include OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, PUR, Hot Tools, Drybar, Curlsmith and Revlon, among others. As of May 31, 2024, we operated two reportable segments: Home & Outdoor and Beauty & Wellness. Our Home & Outdoor segment offers a broad range of outstanding world-class brands that help consumers enjoy everyday living inside their homes and outdoors. Our innovative products for home activities include food preparation and storage, cooking, cleaning, organization, and beverage service. Our outdoor performance range, on-the-go food storage, and beverageware includes lifestyle hydration products, coolers and food storage solutions, backpacks, and travel gear. The Beauty & Wellness segment provides consumers with a broad range of outstanding world-class brands for beauty and wellness. In Beauty, we deliver innovation through products such as hair styling appliances, grooming tools, and liquid and aerosol personal care products that help consumers look and feel more beautiful. In Wellness, we are there when you need us most with highly regarded humidifiers, thermometers, water and air purifiers, heaters, and fans. Our business is seasonal due to different calendar events, holidays and seasonal weather and illness patterns. Our fiscal reporting period ends on the last day in February. Historically, our highest sales volume and operating income occur in our third fiscal quarter ending November 30th. We purchase our products from unaffiliated manufacturers, most of which are located in China, Mexico, Vietnam and the U.S. During fiscal 2023, we initiated a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and effectiveness and reduce costs (referred to as “Project Pegasus”). See Note 6 for additional information. Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates.

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	May 31, 2024
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 2 - New Accounting Pronouncements There have been no changes in the information provided in our Form 10-K.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	May 31, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 3 - Accrued Expenses and Other Current Liabilities A summary of accrued expenses and other current liabilities was as follows: (in thousands) May 31, 2024 February 29, 2024 Accrued compensation, benefits and payroll taxes $ 17,620 $ 36,572 Accrued sales discounts and allowances 40,485 37,851 Accrued sales returns 19,335 21,282 Accrued advertising 27,179 29,212 Other 58,942 56,474 Total accrued expenses and other current liabilities $ 163,561 $ 181,391

Share-Based Compensation Plans

Share-Based Compensation Plans	3 Months Ended
	May 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Note 4 - Share-Based Compensation Plans As part of our compensation structure, we grant share-based compensation awards to certain employees and non-employee members of our Board of Directors during the fiscal year. These awards may be subject to attainment of certain service conditions, performance conditions and/or market conditions. During the first quarter of fiscal 2025, we granted 94,900 service condition awards (“Service Condition Awards”) with a weighted average grant date fair value of $124.37. Additionally, we granted 157,797 performance-based awards during the first quarter of fiscal 2025, of which 94,586 contained performance conditions (“Performance Condition Awards”) and 63,211 contained market conditions (“Market Condition Awards”), with weighted average grant date fair values of $124.37 and $91.19, respectively. Refer to our Form 10-K for further information on the Company's share-based compensation plans. We recorded share-based compensation expense in SG&A as follows: Three Months Ended May 31, (in thousands) 2024 2023 Directors stock compensation $ 196 $ 197 Service Condition Awards 2,568 3,320 Performance Condition Awards 1,047 2,023 Market Condition Awards 1,395 3,147 Employee stock purchase plan 627 610 Share-based compensation expense 5,833 9,297 Less: income tax benefits (264) (641) Share-based compensation expense, net of income tax benefits $ 5,569 $ 8,656 Unrecognized Share-Based Compensation Expense As of May 31, 2024, our total unrecognized share-based compensation for all awards was $33.5 million, which will be recognized over a weighted average amortization period of 2.5 years. The total unrecognized share-based compensation reflects an estimate of target achievement for Performance Condition Awards granted during fiscal 2025 and fiscal 2024 and an estimate of zero percent of target achievement for Performance Condition Awards granted during fiscal 2023.

Repurchases of Common Stock

Repurchases of Common Stock	3 Months Ended
	May 31, 2024
Equity [Abstract]
Repurchases of Common Stock	Note 5 - Repurchases of Common Stock In August 2021, our Board of Directors authorized the repurchase of up to $500 million of our outstanding common stock. The authorization became effective August 25, 2021, for a period of three years, and replaced our former repurchase authorization. As of May 31, 2024, our repurchase authorization allowed for the purchase of $245.4 million of common stock. Our current equity-based compensation plans include provisions that allow for the “net exercise” of share-settled awards by all plan participants. In a net exercise, any required payroll taxes, federal withholding taxes and exercise price of the shares due from the option or other share-based award holders are settled by having the holder tender back to us a number of shares at fair value equal to the amounts due. Net exercises are treated as purchases and retirements of shares. The following table summarizes our share repurchase activity for the periods shown: Three Months Ended May 31, (in thousands, except share and per share data) 2024 2023 Common stock repurchased on the open market: Number of shares 1,011,243 — Aggregate value of shares $ 100,019 $ — Average price per share $ 98.91 $ — Common stock received in connection with share-based compensation: Number of shares 25,372 44,632 Aggregate value of shares $ 3,016 $ 4,446 Average price per share $ 118.85 $ 99.61

Restructuring Plan

Restructuring Plan	3 Months Ended
	May 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring Plan	Note 6 - Restructuring Plan During fiscal 2023, we initiated Project Pegasus, a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and effectiveness and reduce costs. Project Pegasus includes initiatives to further optimize our brand portfolio, streamline and simplify the organization, accelerate and amplify cost of goods savings projects, enhance the efficiency of our supply chain network, optimize our indirect spending and improve our cash flow and working capital, as well as other activities. We anticipate these initiatives will create operating efficiencies, as well as provide a platform to fund future growth investments. During the fourth quarter of fiscal 2023, we made changes to the structure of our organization. These changes resulted in our previous Health & Wellness and Beauty operating segments being combined into a single reportable segment, the creation of a North America Regional Market Organization (“RMO”) responsible for sales and go-to-market strategies for all categories and channels in the U.S. and Canada, and further centralization of certain functions under shared services, particularly in operations and finance to better support our business segments and RMOs. This new structure reduced the size of our global workforce by approximately 10%. We believe that these changes better focus business segment resources on brand development, consumer-centric innovation and marketing, the RMOs on sales and go to market strategies, and shared services on their respective areas of expertise while also creating a more efficient and effective organizational structure. During the second quarter of fiscal 2024, we announced plans to geographically consolidate the U.S. Beauty business, currently located in El Paso, Texas, and Irvine, California, and co-locate it with our Wellness business in the Boston, Massachusetts area. This geographic consolidation and relocation is the next step in our initiative to streamline and simplify the organization and is expected to be completed during fiscal 2025. We expect these changes will enable a greater opportunity to capture synergies and enhance collaboration and innovation within the Beauty & Wellness segment. As previously disclosed, we continue to have the following expectations regarding Project Pegasus charges: • Total one-time pre-tax restructuring charges of approximately $50 million to $55 million over the duration of the plan, expected to be completed during fiscal 2025. • Pre-tax restructuring charges to be comprised of approximately $15 million to $19 million of severance and employee related costs, $28 million of professional fees, $3 million to $4 million of contract termination costs, and $4 million of other exit and disposal costs. • All of our operating segments and shared services will be impacted by the plan and pre-tax restructuring charges include approximately $16 million to $17 million in Home & Outdoor and $34 million to $38 million in Beauty & Wellness. • Pre-tax restructuring charges represent primarily cash expenditures, which are expected to be substantially paid by the end of fiscal 2025. We also continue to have the following expectations regarding Project Pegasus savings: • Targeted annualized pre-tax operating profit improvements of approximately $75 million to $85 million, which began in fiscal 2024 and we expect to be substantially achieved by the end of fiscal 2027. • Estimated cadence of the recognition of the savings will be approximately 25% in fiscal 2024, which was achieved, approximately 35% in fiscal 2025, approximately 25% in fiscal 2026 and approximately 15% in fiscal 2027. • Total profit improvements to be realized approximately 60% through reduced cost of goods sold and 40% through lower SG&A. During the three month periods ended May 31, 2024 and 2023, we incurred $1.8 million and $7.4 million, respectively, of pre-tax restructuring costs in connection with Project Pegasus, which were recorded as “Restructuring charges” in the condensed consolidated statements of income. The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended May 31, 2024 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 440 $ 1,125 $ 1,565 $ 16,841 Professional fees — 270 270 27,147 Contract termination — — — 1,331 Other — — — 2,590 Total restructuring charges $ 440 $ 1,395 $ 1,835 $ 47,909 Three Months Ended May 31, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 484 $ 408 $ 892 Professional fees 2,269 3,357 5,626 Contract termination — 688 688 Other 37 112 149 Total restructuring charges $ 2,790 $ 4,565 $ 7,355 The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 29, 2024 Charges Payments Balance at May 31, 2024 Severance and employee related costs $ 4,493 $ 1,565 $ (2,975) $ 3,083 Professional fees 272 270 (24) 518 Contract termination — — — — Other — — — — Total $ 4,765 $ 1,835 $ (2,999) $ 3,601 (in thousands) Balance at February 28, 2023 Charges Payments Balance at May 31, 2023 Severance and employee related costs $ 3,173 $ 892 $ (2,316) $ 1,749 Professional fees 3,201 5,626 (6,026) 2,801 Contract termination 160 688 (848) — Other 34 149 (183) — Total $ 6,568 $ 7,355 $ (9,373) $ 4,550

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	May 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Commitments and Contingencies Legal Matters We are involved in various legal claims and proceedings in the normal course of operations. We believe the outcome of these matters will not have a material adverse effect on our consolidated financial position, results of operations or liquidity, except as described below. On December 23, 2021, Brita LP filed a complaint against Kaz USA, Inc. and Helen of Troy Limited in the United States District Court for the Western District of Texas (the “Patent Litigation”), alleging patent infringement by the Company relating to its PUR gravity-fed water filtration systems. In the Patent Litigation, Brita LP seeks monetary damages and injunctive relief relating to the alleged infringement. Brita LP simultaneously filed a complaint with the United States International Trade Commission (“ITC”) against Kaz USA, Inc., Helen of Troy Limited and five other unrelated companies that sell water filtration systems (the “ITC Action”). The complaint in the ITC Action also alleged patent infringement by the Company with respect to a limited set of PUR gravity-fed water filtration systems. In the ITC Action, Brita LP requested the ITC to initiate an unfair import investigation relating to such filtration systems. This action sought injunctive relief to prevent entry of certain accused PUR products (and certain other products) into the U.S. and cessation of marketing and sales of existing inventory that is already in the U.S. On January 25, 2022, the ITC instituted the investigation requested by the ITC Action. Discovery closed in the ITC Action in May 2022, and approximately half of the originally identified PUR gravity-fed water filters were removed from the case and are no longer included in the ITC Action. In August 2022, the parties participated in the evidentiary hearing, with additional supplemental hearings in October 2022. On February 28, 2023, the ITC issued an Initial Determination in the ITC Action, tentatively ruling against the Company and the other unrelated respondents. The ITC has a guaranteed review process, and thus all respondents, including the Company, filed a petition with the ITC for a full review of the Initial Determination. On September 19, 2023, the ITC issued its Final Determination in the Company’s favor. The ITC determined there was no violation by the Company and terminated the investigation. Brita LP is appealing the ITC's decision to the Federal Circuit (“CAFC Appeal”) and filed its Notice of Appeal on October 24, 2023. The Company intervened in the CAFC Appeal, but as of the filing date of this Form 10-Q, no hearings have been scheduled. The Patent Litigation remains stayed for the time being. We cannot predict the outcome of these legal proceedings, the amount or range of any potential loss, when the proceedings will be resolved, or customer acceptance of any replacement water filter. Litigation is inherently unpredictable, and the resolution or disposition of these proceedings could, if adversely determined, have a material and adverse impact on our financial position and results of operations. Regulatory Matters During fiscal 2022 and 2023, we were in discussions with the U.S. Environmental Protection Agency (the “EPA”) regarding the compliance of packaging claims on certain of our products in the air and water filtration categories and a limited subset of humidifier products within the Beauty & Wellness segment that are sold in the U.S. The EPA did not raise any product quality, safety or performance issues. As a result of these packaging compliance discussions, we voluntarily implemented a temporary stop shipment action on the impacted products as we worked with the EPA towards an expedient resolution. We resumed normalized levels of shipping of the affected inventory during fiscal 2022 and we completed the repackaging and relabeling of our existing inventory of impacted products during fiscal 2023. Additionally, as a result of continuing dialogue with the EPA, we executed further repackaging and relabeling plans on certain additional humidifier products and certain additional air filtration products, which were also completed during fiscal 2023. Ongoing settlement discussions with the EPA related to this matter may result in the imposition of fines or penalties in the future. Such potential fines or penalties cannot be estimated. For additional information refer to Part I, Item 2., “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including “EPA Compliance Costs”.

Long-Term Debt

Long-Term Debt	3 Months Ended
	May 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Note 8 - Long-Term Debt A summary of our long-term debt follows: (in thousands) May 31, 2024 February 29, 2024 Credit Agreement (1): Revolving loans $ 505,900 $ 421,950 Term loans 248,437 250,000 Total borrowings under Credit Agreement 754,337 671,950 Unamortized prepaid financing fees (5,960) (6,279) Total long-term debt 748,377 665,671 Less: current maturities of long-term debt (7,031) (6,250) Long-term debt, excluding current maturities $ 741,346 $ 659,421 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) inclusive of the impact of our interest rate swaps as of May 31, 2024 and February 29, 2024 were 6.4% and 6.0%, respectively. Capitalized Interest During the three month period ended May 31, 2024, we incurred interest costs totaling $12.5 million, of which none was capitalized, compared to $14.9 million for the same period last year, of which we capitalized $0.9 million as part of property and equipment in connection with the construction of a new distribution facility. Credit Agreement We have a credit agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent, and other lenders that provides for aggregate commitments of $1.5 billion, which are available through (i) a $1.0 billion revolving credit facility, which includes a $50 million sublimit for the issuance of letters of credit, (ii) a $250 million term loan facility, and (iii) a committed $250 million delayed draw term loan facility, which may be borrowed in multiple drawdowns until August 15, 2025. Proceeds can be used for working capital and other general corporate purposes, including funding permitted acquisitions. At the closing date, February 15, 2024, we borrowed $457.5 million under the revolving credit facility and $250.0 million under the term loan facility and utilized the proceeds to repay all debt outstanding under our prior credit agreement. The Credit Agreement matures on February 15, 2029. The Credit Agreement includes an accordion feature, which permits the Company to request to increase its borrowing capacity by an additional $300 million plus an unlimited amount when the Leverage Ratio (as defined in the Credit Agreement) on a pro-forma basis is less than 3.25 to 1.00. The term loans are payable at the end of each fiscal quarter in equal installments of 0.625% through February 28, 2025, 0.9375% through February 28, 2026, and 1.25% thereafter of the original principal balance of the term loans, which began in the first quarter of fiscal 2025, with the remaining balance due at the maturity date. Borrowings under the Credit Agreement bear floating interest at either the Base Rate or Term SOFR (as defined in the Credit Agreement), plus a margin based on the Net Leverage Ratio (as defined in the Credit Agreement) of 0% to 1.125% and 1.0% to 2.125% for Base Rate and Term SOFR borrowings, respectively. The floating interest rates on our borrowings under the Credit Agreement are hedged with interest rate swaps to effectively fix interest rates on $300 million and $500 million of the outstanding principal balance under the revolving loans as of May 31, 2024 and February 29, 2024, respectively. See Notes 9, 10, and 11 for additional information regarding our interest rate swaps. As of May 31, 2024, the balance of outstanding letters of credit was $15.6 million and the amount available for revolving loans under the Credit Agreement was $478.5 million. Covenants in the Credit Agreement limit the amount of total indebtedness we can incur. As of May 31, 2024, these covenants effectively limited our ability to incur more than $336.9 million of additional debt from all sources, including the Credit Agreement, or $478.5 million in the event a qualified acquisition is consummated. Debt Covenants As of May 31, 2024, we were in compliance with all covenants as defined under the terms of the Credit Agreement.

Fair Value

Fair Value	3 Months Ended
	May 31, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 9 - Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques under the accounting guidance related to fair value measurements are based on observable and unobservable inputs. These inputs are classified into the following hierarchy: Level 1: Quoted prices for identical assets or liabilities in active markets; Level 2: Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are classified as Level 2 because their valuation is dependent on observable inputs and other quoted prices for similar assets or liabilities, or model-derived valuations whose significant value drivers are observable. Our investments in U.S. Treasury Bills are classified as Level 1 because their value is based on quoted prices in active markets for identical assets. The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) May 31, 2024 February 29, 2024 Assets: Cash equivalents (money market accounts) $ 3,661 $ 462 U.S. Treasury Bills 9,016 8,948 Interest rate swaps 3,712 2,504 Foreign currency derivatives 432 592 Total assets $ 16,821 $ 12,506 Liabilities: Foreign currency derivatives 505 386 Total liabilities $ 505 $ 386 All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are measured and recorded at fair value on a recurring basis. Our investments in U.S. Treasury Bills are recorded at amortized cost. As of both May 31, 2024 and February 29, 2024, the current and non-current carrying amounts of our U.S. Treasury Bills were $2.5 million and $6.6 million, respectively, and were included within Prepaid expenses and other current assets and Other assets, respectively, in our condensed consolidated balance sheets. The carrying amounts of cash, accounts payable, accrued expenses and other current liabilities and income taxes payable approximate fair value because of the short maturity of these items. The carrying amounts of receivables approximate fair value due to the effect of the related allowance for credit losses. The carrying amount of our floating rate long-term debt approximates its fair value. Our investments in U.S. Treasury Bills are classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. We invest in U.S. Treasury Bills with maturities ranging from less than one We use foreign currency forward contracts and interest rate swaps to manage our exposure to changes in foreign currency exchange rates and interest rates, respectively. All of our derivative assets and liabilities are recorded at fair value. See Notes 10 and 11 for more information on our derivatives.

Financial Instruments and Risk

Financial Instruments and Risk Management	3 Months Ended
	May 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Risk Management	Note 10 - Financial Instruments and Risk Management Foreign Currency Risk The U.S. Dollar is the functional currency for the Company and all of its subsidiaries and is also the reporting currency for the Company. By operating internationally, we are subject to foreign currency risk from transactions denominated in currencies other than the U.S. Dollar (“foreign currencies”). Such transactions include sales and operating expenses. As a result of such transactions, portions of our cash, accounts receivable and accounts payable are denominated in foreign currencies. Approximately 16% and 15% of our net sales revenue was denominated in foreign currencies during the three month periods ended May 31, 2024 and 2023, respectively. These sales were primarily denominated in Euros, British Pounds and Canadian Dollars. We make most of our inventory purchases from manufacturers in Asia and primarily use the U.S. Dollar for such purchases. In our condensed consolidated statements of income, foreign currency exchange rate gains and losses resulting from the remeasurement of foreign income tax receivables and payables, and deferred income tax assets and liabilities are recognized in income tax expense, and all other foreign currency exchange rate gains and losses are recognized in SG&A. During the three month periods ended May 31, 2024 and 2023, we recorded foreign currency exchange rate net losses of $0.1 million and net gains of $0.2 million, respectively, in income tax expense. During the three month periods ended May 31, 2024 and 2023, we recorded foreign currency exchange rate net gains of an immaterial amount and $0.4 million, respectively, in SG&A. We mitigate certain foreign currency exchange rate risk by using forward contracts to protect against the foreign currency exchange rate risk inherent in our transactions denominated in foreign currencies. We do not enter into any derivatives or similar instruments for trading or other speculative purposes. Certain of our forward contracts are designated as cash flow hedges (“foreign currency contracts”) and are recorded on the balance sheet at fair value with changes in fair value recorded in Other Comprehensive Income (Loss) (“OCI”) until the hedge transaction is settled, at which point amounts are reclassified from Accumulated Other Comprehensive Income (Loss) (“AOCI”) to our condensed consolidated statements of income. Foreign currency derivatives for which we have not elected hedge accounting consist of certain forward contracts, and any changes in the fair value of these derivatives are recorded in our condensed consolidated statements of income. These undesignated derivatives are used to hedge monetary net asset and liability positions. Cash flows from our foreign currency derivatives are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. Interest Rate Risk Interest on our outstanding debt as of May 31, 2024 and February 29, 2024 is based on floating interest rates. If short-term interest rates increase, we will incur higher interest expense on any future outstanding balances of floating rate debt. Floating interest rates are hedged with interest rate swaps to effectively fix interest rates on a portion of our outstanding principal balance under the Credit Agreement, which totaled $754.3 million and $672.0 million as of May 31, 2024 and February 29, 2024, respectively. As of May 31, 2024 and February 29, 2024, $300.0 million and $500.0 million of the outstanding principal balance under the Credit Agreement, respectively, was hedged with interest rate swaps to fix the interest rate we pay. Our interest rate swaps are designated as cash flow hedges and are recorded on the balance sheet at fair value with changes in fair value recorded in OCI until the hedge transaction is settled, at which point amounts are reclassified from AOCI to our condensed consolidated statements of income. Cash flows from our interest rate swaps are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) May 31, 2024 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 29,000 $ 249 $ — $ 87 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 18,350 153 — 34 — Forward contracts - sell Pounds Cash flow 11/2025 £ 21,750 16 — 375 2 Forward contracts - sell Norwegian Kroner Cash flow 2/2025 kr 15,000 — — 1 — Interest rate swaps Cash flow 2/2026 $ 300,000 2,127 1,585 — — Subtotal 2,545 1,585 497 2 Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 6/2024 € 1,000 — — 6 — Forward contracts - buy Pounds (1) 6/2024 £ 700 14 — — — Subtotal 14 — 6 — Total fair value $ 2,559 $ 1,585 $ 503 $ 2 (in thousands) February 29, 2024 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 36,500 $ 377 $ — $ 90 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 20,750 151 — 57 — Forward contracts - sell Pounds Cash flow 2/2025 £ 20,250 59 — 234 — Forward contracts - sell Norwegian Kroner Cash flow 8/2024 kr 5,000 5 — — — Interest rate swaps Cash flow 2/2026 $ 500,000 1,314 1,190 — — Subtotal 1,906 1,190 381 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 3/2024 € 430 — — 3 — Forward contracts - sell Pounds (1) 3/2024 £ 735 — — 2 — Subtotal — — 5 — Total fair value $ 1,906 $ 1,190 $ 386 $ — (1) These forward contracts, for which we have not elected hedge accounting, hedge monetary net asset and liability positions for the notional amounts reported, creating an economic hedge against currency movements. The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended May 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ (108) $ (467) Sales revenue, net $ 184 $ 338 Interest rate swaps - cash flow hedges 2,292 (2,634) Interest expense 1,084 1,407 Total $ 2,184 $ (3,101) $ 1,268 $ 1,745 The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended May 31, (in thousands) Location 2024 2023 Forward contracts SG&A $ 22 $ (24) Total $ 22 $ (24) We expect a net gain of $2.0 million associated with foreign currency contracts and interest rate swaps currently recorded in AOCI to be reclassified into income over the next twelve months. The amount ultimately realized, however, will differ as exchange rates and interest rates change and the underlying contracts settle. See Notes 9 and 11 for more information. Counterparty Credit Risk Financial instruments, including foreign currency contracts, forward contracts, and interest rate swaps, expose us to counterparty credit risk for non-performance. We manage our exposure to counterparty credit risk by only dealing with counterparties who are substantial international financial institutions with significant experience using such derivative instruments. We believe that the risk of incurring credit losses is remote.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	May 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 11 - Accumulated Other Comprehensive Income (Loss) The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive loss before reclassification (2,634) (467) (3,101) Amounts reclassified out of AOCI (1,407) (338) (1,745) Tax effects 949 182 1,131 Other comprehensive loss (3,092) (623) (3,715) Balance at May 31, 2023 $ 1,302 $ (70) $ 1,232 Balance at February 29, 2024 $ 1,917 $ 182 $ 2,099 Other comprehensive income (loss) before reclassification 2,292 (108) 2,184 Amounts reclassified out of AOCI (1,084) (184) (1,268) Tax effects (283) 65 (218) Other comprehensive income (loss) 925 (227) 698 Balance at May 31, 2024 $ 2,842 $ (45) $ 2,797 See Notes 9 and 10 for additional information regarding our cash flow hedges.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	May 31, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	Note 12 - Segment and Geographic Information The following tables summarize segment information for the periods presented: Three Months Ended May 31, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 198,459 $ 218,388 $ 416,847 Restructuring charges 440 1,395 1,835 Operating income 15,850 14,913 30,763 Capital and intangible asset expenditures 5,745 3,397 9,142 Depreciation and amortization 6,647 7,189 13,836 Three Months Ended May 31, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 217,144 $ 257,528 $ 474,672 Restructuring charges 2,790 4,565 7,355 Operating income 22,116 18,525 40,641 Capital and intangible asset expenditures 10,960 917 11,877 Depreciation and amortization 4,402 6,313 10,715 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended May 31, (in thousands) 2024 2023 Domestic sales revenue, net (1) $ 300,680 72.1 % $ 359,559 75.7 % International sales revenue, net 116,167 27.9 % 115,113 24.3 % Total sales revenue, net $ 416,847 100.0 % $ 474,672 100.0 % (1)

Income Taxes

Income Taxes	3 Months Ended
	May 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 - Income Taxes We reorganized the Company in Bermuda in 1994 and many of our foreign subsidiaries are not directly or indirectly owned by a U.S. parent. As such, a large portion of our foreign income is not subject to U.S. taxation on a permanent basis under current law. Additionally, our intellectual property is largely owned by foreign subsidiaries, resulting in proportionally higher earnings in jurisdictions with lower statutory tax rates, which decreases our overall effective tax rate. The taxable income earned in each jurisdiction, whether U.S. or foreign, is determined by the subsidiary's operating results and transfer pricing and tax regulations in the related jurisdictions. For interim periods, our income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Organisation for Economic Co-operation and Development has introduced a framework to implement a global minimum corporate income tax of 15%, referred to as “Pillar Two.” Many aspects of Pillar Two are effective for tax years beginning after January 1, 2024, with certain remaining aspects to be effective for tax years beginning January 1, 2025 or later. Certain countries have adopted legislation to implement Pillar Two, and other countries are in the process of introducing legislation to implement Pillar Two. We will continue to assess the impact of Pillar Two and monitor developments in legislation, regulation, and interpretive guidance. In response to Pillar Two, on May 24, 2024, Barbados enacted a domestic corporate income tax rate of 9%, effective beginning with our fiscal year 2025. As a result, we incorporated this corporate income tax into our estimated annual effective tax rate increasing our income tax provision during the first quarter of fiscal 2025. In addition, we revalued our existing deferred tax liabilities subject to the Barbados legislation, which resulted in a discrete tax charge of $6.0 million during the first quarter of fiscal 2025. Additionally, Barbados enacted a domestic minimum top-up tax (“DMTT”) of 15% which applies to Barbados businesses that are part of multinational enterprise groups with annual revenue of €750 million or more and is effective beginning with our fiscal year 2026. We will continue to monitor and evaluate impacts as further regulatory guidance becomes available.

Earnings Per Share

Earnings Per Share	3 Months Ended
	May 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 14 - Earnings Per Share We compute basic earnings per share using the weighted average number of shares of common stock outstanding during the period. We compute diluted earnings per share using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities. Dilutive securities at any given point in time may consist of outstanding options to purchase common stock and issued and contingently issuable unvested restricted stock units, performance stock units, restricted stock awards and performance restricted stock awards and other stock-based awards. Anti-dilutive securities are not included in the computation of diluted earnings per share under the treasury stock method. See Note 4 to these condensed consolidated financial statements for more information regarding stock-based awards. The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended May 31, (in thousands) 2024 2023 Weighted average shares outstanding, basic 23,524 24,049 Incremental shares from share-based compensation arrangements 109 85 Weighted average shares outstanding, diluted 23,633 24,134 Anti-dilutive securities 125 156

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Pay vs Performance Disclosure
Net income	$ 6,204	$ 22,581

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	May 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Rel_2

Basis of Presentation and Related Information (Policies)	3 Months Ended
	May 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates.

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	May 31, 2024
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	A summary of accrued expenses and other current liabilities was as follows: (in thousands) May 31, 2024 February 29, 2024 Accrued compensation, benefits and payroll taxes $ 17,620 $ 36,572 Accrued sales discounts and allowances 40,485 37,851 Accrued sales returns 19,335 21,282 Accrued advertising 27,179 29,212 Other 58,942 56,474 Total accrued expenses and other current liabilities $ 163,561 $ 181,391

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	3 Months Ended
	May 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense in SG&A	We recorded share-based compensation expense in SG&A as follows: Three Months Ended May 31, (in thousands) 2024 2023 Directors stock compensation $ 196 $ 197 Service Condition Awards 2,568 3,320 Performance Condition Awards 1,047 2,023 Market Condition Awards 1,395 3,147 Employee stock purchase plan 627 610 Share-based compensation expense 5,833 9,297 Less: income tax benefits (264) (641) Share-based compensation expense, net of income tax benefits $ 5,569 $ 8,656

Repurchases of Common Stock (Ta

Repurchases of Common Stock (Tables)	3 Months Ended
	May 31, 2024
Equity [Abstract]
Summary of share repurchase activity	The following table summarizes our share repurchase activity for the periods shown: Three Months Ended May 31, (in thousands, except share and per share data) 2024 2023 Common stock repurchased on the open market: Number of shares 1,011,243 — Aggregate value of shares $ 100,019 $ — Average price per share $ 98.91 $ — Common stock received in connection with share-based compensation: Number of shares 25,372 44,632 Aggregate value of shares $ 3,016 $ 4,446 Average price per share $ 118.85 $ 99.61

Restructuring Plan (Tables)

Restructuring Plan (Tables)	3 Months Ended
	May 31, 2024
Restructuring and Related Activities [Abstract]
Summary of restructuring charges recorded	The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended May 31, 2024 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 440 $ 1,125 $ 1,565 $ 16,841 Professional fees — 270 270 27,147 Contract termination — — — 1,331 Other — — — 2,590 Total restructuring charges $ 440 $ 1,395 $ 1,835 $ 47,909 Three Months Ended May 31, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 484 $ 408 $ 892 Professional fees 2,269 3,357 5,626 Contract termination — 688 688 Other 37 112 149 Total restructuring charges $ 2,790 $ 4,565 $ 7,355
Rollforward of restructuring reserve	The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 29, 2024 Charges Payments Balance at May 31, 2024 Severance and employee related costs $ 4,493 $ 1,565 $ (2,975) $ 3,083 Professional fees 272 270 (24) 518 Contract termination — — — — Other — — — — Total $ 4,765 $ 1,835 $ (2,999) $ 3,601 (in thousands) Balance at February 28, 2023 Charges Payments Balance at May 31, 2023 Severance and employee related costs $ 3,173 $ 892 $ (2,316) $ 1,749 Professional fees 3,201 5,626 (6,026) 2,801 Contract termination 160 688 (848) — Other 34 149 (183) — Total $ 6,568 $ 7,355 $ (9,373) $ 4,550

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	May 31, 2024
Debt Disclosure [Abstract]
Summary of long-term debt	A summary of our long-term debt follows: (in thousands) May 31, 2024 February 29, 2024 Credit Agreement (1): Revolving loans $ 505,900 $ 421,950 Term loans 248,437 250,000 Total borrowings under Credit Agreement 754,337 671,950 Unamortized prepaid financing fees (5,960) (6,279) Total long-term debt 748,377 665,671 Less: current maturities of long-term debt (7,031) (6,250) Long-term debt, excluding current maturities $ 741,346 $ 659,421 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) inclusive of the impact of our interest rate swaps as of May 31, 2024 and February 29, 2024 were 6.4% and 6.0%, respectively.

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	May 31, 2024
Fair Value Disclosures [Abstract]
Schedule of carrying value and fair value of financial assets and liabilities recorded at fair value and measured on a recurring basis and classified as level 2	The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) May 31, 2024 February 29, 2024 Assets: Cash equivalents (money market accounts) $ 3,661 $ 462 U.S. Treasury Bills 9,016 8,948 Interest rate swaps 3,712 2,504 Foreign currency derivatives 432 592 Total assets $ 16,821 $ 12,506 Liabilities: Foreign currency derivatives 505 386 Total liabilities $ 505 $ 386

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	3 Months Ended
	May 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair values of derivative instruments	The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) May 31, 2024 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 29,000 $ 249 $ — $ 87 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 18,350 153 — 34 — Forward contracts - sell Pounds Cash flow 11/2025 £ 21,750 16 — 375 2 Forward contracts - sell Norwegian Kroner Cash flow 2/2025 kr 15,000 — — 1 — Interest rate swaps Cash flow 2/2026 $ 300,000 2,127 1,585 — — Subtotal 2,545 1,585 497 2 Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 6/2024 € 1,000 — — 6 — Forward contracts - buy Pounds (1) 6/2024 £ 700 14 — — — Subtotal 14 — 6 — Total fair value $ 2,559 $ 1,585 $ 503 $ 2 (in thousands) February 29, 2024 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 36,500 $ 377 $ — $ 90 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 20,750 151 — 57 — Forward contracts - sell Pounds Cash flow 2/2025 £ 20,250 59 — 234 — Forward contracts - sell Norwegian Kroner Cash flow 8/2024 kr 5,000 5 — — — Interest rate swaps Cash flow 2/2026 $ 500,000 1,314 1,190 — — Subtotal 1,906 1,190 381 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 3/2024 € 430 — — 3 — Forward contracts - sell Pounds (1) 3/2024 £ 735 — — 2 — Subtotal — — 5 — Total fair value $ 1,906 $ 1,190 $ 386 $ — (1)
Schedule of pre-tax effect of derivative instruments designated as hedges	The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended May 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ (108) $ (467) Sales revenue, net $ 184 $ 338 Interest rate swaps - cash flow hedges 2,292 (2,634) Interest expense 1,084 1,407 Total $ 2,184 $ (3,101) $ 1,268 $ 1,745
Schedule of pre-tax effect of derivative instruments not designated as hedges	The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended May 31, (in thousands) Location 2024 2023 Forward contracts SG&A $ 22 $ (24) Total $ 22 $ (24)

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	May 31, 2024
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Summary of changes in accumulated other comprehensive income (loss)	The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive loss before reclassification (2,634) (467) (3,101) Amounts reclassified out of AOCI (1,407) (338) (1,745) Tax effects 949 182 1,131 Other comprehensive loss (3,092) (623) (3,715) Balance at May 31, 2023 $ 1,302 $ (70) $ 1,232 Balance at February 29, 2024 $ 1,917 $ 182 $ 2,099 Other comprehensive income (loss) before reclassification 2,292 (108) 2,184 Amounts reclassified out of AOCI (1,084) (184) (1,268) Tax effects (283) 65 (218) Other comprehensive income (loss) 925 (227) 698 Balance at May 31, 2024 $ 2,842 $ (45) $ 2,797

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	May 31, 2024
Segment Reporting [Abstract]
Schedule of segment information	The following tables summarize segment information for the periods presented: Three Months Ended May 31, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 198,459 $ 218,388 $ 416,847 Restructuring charges 440 1,395 1,835 Operating income 15,850 14,913 30,763 Capital and intangible asset expenditures 5,745 3,397 9,142 Depreciation and amortization 6,647 7,189 13,836 Three Months Ended May 31, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 217,144 $ 257,528 $ 474,672 Restructuring charges 2,790 4,565 7,355 Operating income 22,116 18,525 40,641 Capital and intangible asset expenditures 10,960 917 11,877 Depreciation and amortization 4,402 6,313 10,715 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended May 31, (in thousands) 2024 2023 Domestic sales revenue, net (1) $ 300,680 72.1 % $ 359,559 75.7 % International sales revenue, net 116,167 27.9 % 115,113 24.3 % Total sales revenue, net $ 416,847 100.0 % $ 474,672 100.0 % (1)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	May 31, 2024
Earnings Per Share [Abstract]
Schedule of components of basic and diluted shares	The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended May 31, (in thousands) 2024 2023 Weighted average shares outstanding, basic 23,524 24,049 Incremental shares from share-based compensation arrangements 109 85 Weighted average shares outstanding, diluted 23,633 24,134 Anti-dilutive securities 125 156

Basis of Presentation and Rel_3

Basis of Presentation and Related Information (Details)	3 Months Ended
	May 31, 2024 segment $ / shares	Feb. 29, 2024 $ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Common shares, par value (in dollars per share) | $ / shares	$ 0.10	$ 0.10
Number of segments | segment	2

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	May 31, 2024	Feb. 29, 2024
Payables and Accruals [Abstract]
Accrued compensation, benefits and payroll taxes	$ 17,620	$ 36,572
Accrued sales discounts and allowances	40,485	37,851
Accrued sales returns	19,335	21,282
Accrued advertising	27,179	29,212
Other	58,942	56,474
Accrued expenses and other current liabilities	$ 163,561	$ 181,391

Share-Based Compensation Plan_2

Share-Based Compensation Plans - Narrative (Details) $ / shares in Units, $ in Millions	3 Months Ended
	May 31, 2024 USD ($) $ / shares shares
Share-based compensation plans
Expected recognition period for unrecognized share-based compensation	2 years 6 months
Target achievement for performance condition awards, as a percentage	0%
Restricted Stock
Share-based compensation plans
Number of awards granted (in shares)	157,797
Unrecognized share-based compensation | $	$ 33.5
Service Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	94,900
Grant date fair value of shares granted in period (in dollars per share) | $ / shares	$ 124.37
Market Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	63,211
Grant date fair value of shares granted in period (in dollars per share) | $ / shares	$ 91.19
Performance Condition Awards
Share-based compensation plans
Number of awards granted (in shares)	94,586
Grant date fair value of shares granted in period (in dollars per share) | $ / shares	$ 124.37

Share-Based Compensation Plan_3

Share-Based Compensation Plans - Share-Based Compensation Expense in SG&A (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense, net of income tax benefits	$ 5,569	$ 8,656
SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	5,833	9,297
Less: income tax benefits	(264)	(641)
Service Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	2,568	3,320
Performance Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,047	2,023
Market Condition Awards | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	1,395	3,147
Employee stock purchase plan | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	627	610
Directors stock compensation | SG&A
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 196	$ 197

Repurchases of Common Stock - N

Repurchases of Common Stock - Narrative (Details) - USD ($)	Aug. 25, 2021	May 31, 2024	Aug. 31, 2021
Equity [Abstract]
Amount of shares authorized for purchase			$ 500,000,000
Period for stock repurchase	3 years
Remaining share repurchase amount		$ 245,400,000

Repurchases of Common Stock - S

Repurchases of Common Stock - Summary of Share Repurchase Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Repurchase of common stock
Aggregate value of shares	$ 103,035	$ 4,446
Stock Compensation Plan
Repurchase of common stock
Number of shares (in shares)	25,372	44,632
Aggregate value of shares	$ 3,016	$ 4,446
Average price per share (in dollars per share)	$ 118.85	$ 99.61
Open Market
Repurchase of common stock
Number of shares (in shares)	1,011,243	0
Aggregate value of shares	$ 100,019	$ 0
Average price per share (in dollars per share)	$ 98.91	$ 0

Restructuring Plan - Narrative

Restructuring Plan - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		24 Months Ended
	May 31, 2024	May 31, 2023	May 31, 2024	Feb. 29, 2024	Aug. 31, 2023
Restructuring Plan
Restructuring charges	$ 1,835	$ 7,355
Project Pegasus
Restructuring Plan
Estimated percentage of workforce reduction				10%
Estimated percentage reduction in cost of goods sold	60%
Estimated percentage reduction in SG&A expenses	40%
Restructuring charges	$ 1,835	7,355	$ 47,909
Project Pegasus | Home & Outdoor
Restructuring Plan
Restructuring charges	440	2,790
Project Pegasus | Beauty & Wellness
Restructuring Plan
Restructuring charges	1,395	4,565
Project Pegasus | Severance and employee related costs
Restructuring Plan
Restructuring charges	1,565	892
Project Pegasus | Professional fees
Restructuring Plan
Expected restructuring costs					$ 28,000
Restructuring charges	270	5,626
Project Pegasus | Contract termination
Restructuring Plan
Restructuring charges	0	688
Project Pegasus | Other
Restructuring Plan
Restructuring charges	$ 0	$ 149
Project Pegasus | Fiscal 2024
Restructuring Plan
Estimated percentage of savings recognized	25%
Project Pegasus | Fiscal 2025
Restructuring Plan
Estimated percentage of savings recognized	35%
Project Pegasus | Fiscal 2026
Restructuring Plan
Estimated percentage of savings recognized	25%
Project Pegasus | Fiscal 2027
Restructuring Plan
Estimated percentage of savings recognized	15%
Project Pegasus | Minimum
Restructuring Plan
Expected restructuring costs					50,000
Annualized profit improvements	$ 75,000
Project Pegasus | Minimum | Home & Outdoor
Restructuring Plan
Expected restructuring costs					16,000
Project Pegasus | Minimum | Beauty & Wellness
Restructuring Plan
Expected restructuring costs					34,000
Project Pegasus | Minimum | Severance and employee related costs
Restructuring Plan
Expected restructuring costs					15,000
Project Pegasus | Minimum | Contract termination
Restructuring Plan
Expected restructuring costs					3,000
Project Pegasus | Maximum
Restructuring Plan
Expected restructuring costs					55,000
Annualized profit improvements	$ 85,000
Project Pegasus | Maximum | Home & Outdoor
Restructuring Plan
Expected restructuring costs					17,000
Project Pegasus | Maximum | Beauty & Wellness
Restructuring Plan
Expected restructuring costs					38,000
Project Pegasus | Maximum | Severance and employee related costs
Restructuring Plan
Expected restructuring costs					19,000
Project Pegasus | Maximum | Contract termination
Restructuring Plan
Expected restructuring costs					4,000
Project Pegasus | Maximum | Other
Restructuring Plan
Expected restructuring costs					$ 4,000

Restructuring Plan - Restructur

Restructuring Plan - Restructuring Charges to Date (Details) - USD ($) $ in Thousands	3 Months Ended		24 Months Ended
	May 31, 2024	May 31, 2023	May 31, 2024
Restructuring Plan
Total restructuring charges	$ 1,835	$ 7,355
Project Pegasus
Restructuring Plan
Severance and employee related costs	1,565	892	$ 16,841
Professional fees	270	5,626	27,147
Contract termination	0	688	1,331
Other	0	149	2,590
Total restructuring charges	1,835	7,355	$ 47,909
Home & Outdoor | Project Pegasus
Restructuring Plan
Severance and employee related costs	440	484
Professional fees	0	2,269
Contract termination	0	0
Other	0	37
Total restructuring charges	440	2,790
Beauty & Wellness | Project Pegasus
Restructuring Plan
Severance and employee related costs	1,125	408
Professional fees	270	3,357
Contract termination	0	688
Other	0	112
Total restructuring charges	$ 1,395	$ 4,565

Restructuring Plan - Reserve Ro

Restructuring Plan - Reserve Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended		24 Months Ended
	May 31, 2024	May 31, 2023	May 31, 2024
Restructuring Reserve [Roll Forward]
Charges	$ 1,835	$ 7,355
Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	4,765	6,568
Charges	1,835	7,355	$ 47,909
Payments	(2,999)	(9,373)
Restructuring liability, ending balance	3,601	4,550	3,601
Severance and employee related costs | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	4,493	3,173
Charges	1,565	892
Payments	(2,975)	(2,316)
Restructuring liability, ending balance	3,083	1,749	3,083
Professional fees | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	272	3,201
Charges	270	5,626
Payments	(24)	(6,026)
Restructuring liability, ending balance	518	2,801	518
Contract termination | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	0	160
Charges	0	688
Payments	0	(848)
Restructuring liability, ending balance	0	0	0
Other | Project Pegasus
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	0	34
Charges	0	149
Payments	0	(183)
Restructuring liability, ending balance	$ 0	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details)	Dec. 23, 2021 renewal
Commitments and Contingencies Disclosure [Abstract]
Number of other companies named in litigation	5

Long-Term Debt - Schedule (Deta

Long-Term Debt - Schedule (Details) - USD ($) $ in Thousands	May 31, 2024	Feb. 29, 2024
Long-term debt
Unamortized prepaid financing fees	$ (5,960)	$ (6,279)
Total long-term debt	748,377	665,671
Less: current maturities of long-term debt	(7,031)	(6,250)
Long-term debt, excluding current maturities	$ 741,346	$ 659,421
Line of credit
Long-term debt
Weighted average effective interest rate	6.40%	6%
Line of credit | Credit Agreement
Long-term debt
Aggregate principal balance	$ 754,337	$ 671,950
Line of credit | Credit Agreement | Revolving loans
Long-term debt
Aggregate principal balance	505,900	421,950
Line of credit | Credit Agreement | Term loans
Long-term debt
Aggregate principal balance	$ 248,437	$ 250,000

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) $ in Thousands		3 Months Ended
	Feb. 15, 2024 USD ($)	May 31, 2024 USD ($)	May 31, 2023 USD ($)	Feb. 29, 2024 USD ($)
Debt Instrument [Line Items]
Interest costs incurred		$ 12,500	$ 14,900
Interest costs capitalized		0	$ 900
Maximum net leverage ratio	3.25
Term loans
Debt Instrument [Line Items]
Aggregate principal amount	$ 250,000
Revolving loans | Credit Agreement
Debt Instrument [Line Items]
Maximum revolving commitment	1,500,000
Line of credit
Debt Instrument [Line Items]
Fixed rate debt		300,000		$ 500,000
Maximum additional debt allowed under debt covenants		336,900
Maximum additional debt allowed in the event a qualified acquisition is consummated		478,500
Line of credit | Credit Agreement
Debt Instrument [Line Items]
Maximum allowable increase due to accordion feature	$ 300,000
Line of credit | Credit Agreement | Minimum | Base rate | Variable Rate Component One
Debt Instrument [Line Items]
Margin (as a percent)	0%
Line of credit | Credit Agreement | Minimum | SOFR | Variable Rate Component Two
Debt Instrument [Line Items]
Margin (as a percent)	1%
Line of credit | Credit Agreement | Maximum | Base rate | Variable Rate Component One
Debt Instrument [Line Items]
Margin (as a percent)	1.125%
Line of credit | Credit Agreement | Maximum | SOFR | Variable Rate Component Two
Debt Instrument [Line Items]
Margin (as a percent)	2.125%
Line of credit | Revolving loans | Credit Agreement
Debt Instrument [Line Items]
Maximum revolving commitment	$ 1,000,000
Proceeds from revolving credit facility	457,500
Fixed rate debt		300,000		$ 500,000
Amount available for borrowings		478,500
Line of credit | Letter of credit
Debt Instrument [Line Items]
Amount outstanding, letters of credit		$ 15,600
Line of credit | Letter of credit | Credit Agreement
Debt Instrument [Line Items]
Maximum revolving commitment	50,000
Line of credit | Term loans | Credit Agreement
Debt Instrument [Line Items]
Proceeds from term loan facility	$ 250,000
Line of credit | Term loans | Credit Agreement | Through February 28, 2025
Debt Instrument [Line Items]
Percent of term loans due quarterly	0.625%
Line of credit | Term loans | Credit Agreement | Through February 28, 2026
Debt Instrument [Line Items]
Percent of term loans due quarterly	0.9375%
Line of credit | Term loans | Credit Agreement | After February 28th, 2026
Debt Instrument [Line Items]
Percent of term loans due quarterly	1.25%
Line of credit | Delayed Draw Term Loan (DDTL) | Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount	$ 250,000

Fair Value - Summary of Financi

Fair Value - Summary of Financial Assets and Liabilities (Details) - Recurring - Fair Values - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	May 31, 2024	Feb. 29, 2024
Assets:
Cash equivalents (money market accounts)	$ 3,661	$ 462
Total assets	16,821	12,506
Liabilities:
Total liabilities	505	386
Interest rate swaps
Assets:
Derivative assets	3,712	2,504
Foreign currency derivatives
Assets:
Derivative assets	432	592
Liabilities:
Derivative liabilities	505	386
U.S. Treasury Bills
Assets:
U.S. Treasury Bills	$ 9,016	$ 8,948

Fair Value - Narrative (Details

Fair Value - Narrative (Details) - U.S. Treasury Bills - USD ($) $ in Millions	3 Months Ended
	May 31, 2024	Feb. 29, 2024
Fair Value
Unrealized loss on US Treasury bills	$ 0.1
Minimum
Fair Value
Term of US treasury bills held to maturity (less than one to five years)	1 year
Maximum
Fair Value
Term of US treasury bills held to maturity (less than one to five years)	5 years
Prepaid Expenses and Other Current Assets
Fair Value
US treasury bills, carrying value, current	$ 2.5	$ 2.5
Other Assets
Fair Value
US treasury bills, carrying value, non-current	$ 6.6	$ 6.6

Financial Instruments and Ris_3

Financial Instruments and Risk Management - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023	Feb. 29, 2024
Foreign currency derivatives | Cash flow hedges
Foreign Currency Risk and Currency Exchange Uncertainties
Net gain reported in AOCI to be reclassified	$ (2,000)
Period of reclassification to AOCI	12 months
Credit agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Fixed rate debt	$ 300,000		$ 500,000
Credit agreement | Credit Agreement
Foreign Currency Risk and Currency Exchange Uncertainties
Aggregate principal balance	754,337		$ 671,950
SG&A
Foreign Currency Risk and Currency Exchange Uncertainties
Net foreign exchange gains (losses), including the impact of currency hedges and currency swaps		$ 400
Income Tax Expense
Foreign Currency Risk and Currency Exchange Uncertainties
Net foreign exchange gains (losses), including the impact of currency hedges and currency swaps	$ 100	$ 200
Net sales revenue | Geographic concentration | International operations - transactions denominated in foreign currencies
Foreign Currency Risk and Currency Exchange Uncertainties
Concentration risk percentage	16%	15%

Financial Instruments and Ris_4

Financial Instruments and Risk Management - Derivative FV (Details) € in Thousands, £ in Thousands, kr in Thousands, $ in Thousands, $ in Thousands	May 31, 2024 EUR (€)	May 31, 2024 USD ($)	May 31, 2024 CAD ($)	May 31, 2024 GBP (£)	May 31, 2024 NOK (kr)	Feb. 29, 2024 EUR (€)	Feb. 29, 2024 USD ($)	Feb. 29, 2024 CAD ($)	Feb. 29, 2024 GBP (£)	Feb. 29, 2024 NOK (kr)
Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		$ 2,559					$ 1,906
Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,585					1,190
Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		503					386
Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		2					0
Derivatives designated as hedging instruments | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		2,545					1,906
Derivatives designated as hedging instruments | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,585					1,190
Derivatives designated as hedging instruments | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		497					381
Derivatives designated as hedging instruments | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		2					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount			$ 18,350	£ 21,750	kr 15,000	€ 36,500		$ 20,750	£ 20,250	kr 5,000
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount | €	€ 29,000
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		249					377
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		87					90
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		153					151
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		34					57
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		16					59
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		375					234
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		2					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					5
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		1					0
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Interest rate swaps
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount		300,000					500,000
Derivatives designated as hedging instruments | Interest rate swaps | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		2,127					1,314
Derivatives designated as hedging instruments | Interest rate swaps | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		1,585					1,190
Derivatives designated as hedging instruments | Interest rate swaps | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives designated as hedging instruments | Interest rate swaps | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		14					0
Derivatives not designated under hedge accounting | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0					0
Derivatives not designated under hedge accounting | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		6					5
Derivatives not designated under hedge accounting | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0					0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							3
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets							0
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							2
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities							$ 0
Derivatives not designated under hedge accounting | Cross currency debt swaps
Fair values of derivative instruments in the consolidated balance sheet
Notional Amount	€ 1,000			£ 700		€ 430			£ 735
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		6
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Prepaid Expenses and Other Current Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		14
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Assets
Fair values of derivative instruments in the consolidated balance sheet
Derivative assets		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Accrued Expenses and Other Current Liabilities
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		0
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Liabilities, Non- Current
Fair values of derivative instruments in the consolidated balance sheet
Derivative liabilities		$ 0

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Derivative Tax Effect (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	$ 2,184	$ (3,101)
Gain (Loss) Reclassified from AOCI into Income	1,268	1,745
Gain (Loss)  Recognized in Income	22	(24)
Foreign currency derivatives | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	(108)	(467)
Foreign currency derivatives | Cash flow hedges | SG&A
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	184	338
Interest rate swaps | Cash flow hedges
Pre-tax effect of derivative instruments
Gain (Loss) Recognized in AOCI	2,292	(2,634)
Interest rate swaps | Cash flow hedges | Interest expense
Pre-tax effect of derivative instruments
Gain (Loss) Reclassified from AOCI into Income	1,084	1,407
Forward contracts | SG&A
Pre-tax effect of derivative instruments
Gain (Loss)  Recognized in Income	$ 22	$ (24)

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 1,637,442	$ 1,488,811
Other comprehensive income (loss) before reclassification	2,184	(3,101)
Amounts reclassified out of AOCI	(1,268)	(1,745)
Tax effects	(218)	1,131
Total other comprehensive income (loss), net of tax	698	(3,715)
Ending balance	1,549,500	1,514,908
Interest Rate Swaps
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	1,917	4,394
Other comprehensive income (loss) before reclassification	2,292	(2,634)
Amounts reclassified out of AOCI	(1,084)	(1,407)
Tax effects	(283)	949
Total other comprehensive income (loss), net of tax	925	(3,092)
Ending balance	2,842	1,302
Foreign Currency Contracts
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	182	553
Other comprehensive income (loss) before reclassification	(108)	(467)
Amounts reclassified out of AOCI	(184)	(338)
Tax effects	65	182
Total other comprehensive income (loss), net of tax	(227)	(623)
Ending balance	(45)	(70)
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	2,099	4,947
Total other comprehensive income (loss), net of tax	698	(3,715)
Ending balance	$ 2,797	$ 1,232

Segment and Geographic Inform_3

Segment and Geographic Information - Segment Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Segment information
Sales revenue, net	$ 416,847	$ 474,672
Restructuring charges	1,835	7,355
Operating income	30,763	40,641
Capital and intangible asset expenditures	9,142	11,877
Depreciation and amortization	13,836	10,715
Operating Segments
Segment information
Sales revenue, net	416,847	474,672
Restructuring charges	1,835	7,355
Operating income	30,763	40,641
Capital and intangible asset expenditures	9,142	11,877
Depreciation and amortization	13,836	10,715
Home & Outdoor | Operating Segments
Segment information
Sales revenue, net	198,459	217,144
Restructuring charges	440	2,790
Operating income	15,850	22,116
Capital and intangible asset expenditures	5,745	10,960
Depreciation and amortization	6,647	4,402
Beauty & Wellness | Operating Segments
Segment information
Sales revenue, net	218,388	257,528
Restructuring charges	1,395	4,565
Operating income	14,913	18,525
Capital and intangible asset expenditures	3,397	917
Depreciation and amortization	$ 7,189	$ 6,313

Segment and Geographic Inform_4

Segment and Geographic Information - Revenue by Domestic and International (Details) - USD ($) $ in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Segment information
Sales revenue, net	$ 416,847	$ 474,672
Domestic sales revenue, net
Segment information
Sales revenue, net	300,680	359,559
International sales revenue, net
Segment information
Sales revenue, net	$ 116,167	$ 115,113
Revenue from Contract with Customer Benchmark | Geographic concentration
Segment information
Concentration risk percentage	100%	100%
Revenue from Contract with Customer Benchmark | Geographic concentration | Domestic sales revenue, net
Segment information
Concentration risk percentage	72.10%	75.70%
Revenue from Contract with Customer Benchmark | Geographic concentration | International sales revenue, net
Segment information
Concentration risk percentage	27.90%	24.30%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	May 31, 2024	May 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Income tax expense (benefit) as a percent of income before income taxes	66.10%	15.50%
Foreign Tax Authority | Barbados Revenue Authority
Effective Income Tax Rate Reconciliation [Line Items]
Discrete tax charge due to change in legislation	$ 6

Earnings per Share (Details)

Earnings per Share (Details) - shares shares in Thousands	3 Months Ended
	May 31, 2024	May 31, 2023
Weighted average diluted securities
Weighted average shares outstanding, basic (in shares)	23,524	24,049
Incremental shares from share-based payment arrangements (in shares)	109	85
Weighted average shares outstanding, diluted (in shares)	23,633	24,134
Anti-dilutive securities
Weighted average diluted securities
Antidilutive securities (in shares)	125	156